Drug Profile
ID 085
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Idorsia Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Unspecified in Switzerland (PO, Capsule)
- 15 Apr 2019 Idorsia Phamaceuticals plans a phase I pharmacokinetics trial in healthy volunteers and patients with renal impairment in Germany in April 2019 , (NCT03913000)
- 13 Dec 2017 Preclinical trials in Undefined indication in Switzerland (PO) before December 2017 (NCT03372629)